<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: communications", fill: "#fe2712"},
{source: "1: communications", target: "1: statements about", fill: "#fe2712"},
{source: "1: statements about", target: "1: discovery", fill: "#fe2712"},
{source: "1: discovery", target: "1: development", fill: "#fe2712"},
{source: "1: development", target: "1: intellectual property", fill: "#fe2712"},
{source: "1: communications", target: "10: successfully conduct", fill: "#536878"},
{source: "10: successfully conduct", target: "10: clinical trials", fill: "#536878"},
{source: "10: clinical trials", target: "10: appropriate regulatory", fill: "#536878"},
{source: "10: successfully conduct", target: "26: collaborations", fill: "#014421"},
{source: "26: collaborations", target: "26: transfer responsibility", fill: "#014421"},
{source: "26: transfer responsibility", target: "26: regulatory", fill: "#014421"},
{source: "26: regulatory", target: "26: requirements", fill: "#014421"},
{source: "26: requirements", target: "26: such as filing", fill: "#014421"},
{source: "26: such as filing", target: "26: authorizations", fill: "#014421"},
{source: "26: authorizations", target: "26: collaborators", fill: "#014421"},
{source: "26: collaborations", target: "32: revenues over", fill: "#51484f"},
{source: "32: revenues over", target: "32: next several years will", fill: "#51484f"},
{source: "32: next several years will", target: "32: materially dependent on", fill: "#51484f"},
{source: "32: materially dependent on", target: "32: commercial success", fill: "#51484f"},
{source: "32: commercial success", target: "32: two currently marketed products", fill: "#51484f"},
{source: "32: two currently marketed products", target: "32: INTEGRILIN VELCADE ", fill: "#51484f"},
{source: "32: INTEGRILIN VELCADE ", target: "32: approved by", fill: "#51484f"},
{source: "32: approved by", target: "32: FDA in May ", fill: "#51484f"},
{source: "32: FDA in May ", target: "32: commercially", fill: "#51484f"},
{source: "32: commercially", target: "32: United States ", fill: "#51484f"},
{source: "32: revenues over", target: "34: INTEGRILIN ", fill: "#a0785a"},
{source: "34: INTEGRILIN ", target: "34: United States ", fill: "#a0785a"},
{source: "34: INTEGRILIN ", target: "39: competition", fill: "#bb3385"},
{source: "39: competition", target: "39: others may discover", fill: "#bb3385"},
{source: "39: others may discover", target: "39: commercialize products", fill: "#bb3385"},
{source: "39: commercialize products", target: "39: successfully than", fill: "#bb3385"},
{source: "39: competition", target: "42: Furthermore ", fill: "#e6e200"},
{source: "42: Furthermore ", target: "42: competitors", fill: "#e6e200"},
{source: "42: competitors", target: "42: drug research discovery", fill: "#e6e200"},
{source: "42: drug research discovery", target: "42: development", fill: "#e6e200"},
{source: "42: development", target: "42: commercialization", fill: "#e6e200"},
{source: "42: commercialization", target: "42: regulatory approvals", fill: "#e6e200"},
{source: "42: regulatory approvals", target: "42: manufacturing", fill: "#e6e200"},
{source: "42: Furthermore ", target: "START_HERE", fill: "#e6e200"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_Trials_Directive">Clinical Trials Directive</a></td>
      <td>The Clinical Trials Directive (Officially Directive 2001/20/EC of 4 April 2001, of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborators_(Battlestar_Galactica)">Collaborators (Battlestar Galactica)</a></td>
      <td>"Collaborators"  is the fifth episode of the third season from the science fiction television series Battlestar Galactica.\nThis is the first episode of season 3 to include a survivor count, at 41,435, down considerably from the 49,550 shown in "Lay Down Your Burdens" (Part 2).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Eptifibatide">Eptifibatide</a></td>
      <td>Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein (P22827) found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Glycoprotein_IIb/IIIa_inhibitors">Glycoprotein IIb/IIIa inhibitors</a></td>
      <td>In medicine, glycoprotein IIb/IIIa (GPIIb/IIIa, also known as integrin αIIbβ3) is an integrin complex found on platelets. It is a receptor for fibrinogen and von Willebrand factor and aids platelet activation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Antiplatelet_drug">Antiplatelet drug</a></td>
      <td>An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation. They are effective in the arterial circulation where anticoagulants have little effect.They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Percutaneous_coronary_intervention">Percutaneous coronary intervention</a></td>
      <td>Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat narrowing of the coronary arteries of the heart found in coronary artery disease. The process involves combining coronary angioplasty with stenting, which is the insertion of a permanent wire-meshed tube that is either drug eluting (DES) or composed of bare metal (BMS).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_GSK_plc_products">List of GSK plc products</a></td>
      <td>This is a list of products manufactured by the multinational pharmaceutical, biologics, vaccines and consumer healthcare company GSK.\n\n\n== Pharmaceutical products ==\n\n\n== Vaccines ==\n\n\n== Consumer healthcare products ==\nAbreva (Docosanol)\nAdvil (Ibuprofen)\nalli (Orlistat)\nAquafresh (oral healthcare)\nAstring-o-Sol (oral healthcare)\nBeechams Cold &amp; Flu and Night/Day Nurse (cold and flu treatments)\nBinaca (oral healthcare)\nBiotene (oral healthcare)\nBoost (nutritional)\nBreathe Right (respiratory)\nCentrum (vitamins and naturals)\nCetebe (vitamins and naturals)\nChlorhexamed (oral healthcare)\nCholinex (analgesics and respiratory tract)\nCitrucel (gastrointestinal)\nColdrex (cold and flu treatment)\nCommit Lozenge (smoking cessation)\nCommitted Quitters (nicotine replacement)\nCorega (oral healthcare)\nCorsodyl (oral healthcare)\nCrocin (analgesics and respiratory tract)\nDr.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arginylglycylaspartic_acid">Arginylglycylaspartic acid</a></td>
      <td>Arginylglycylaspartic acid (RGD) is the most common peptide motif responsible for cell adhesion to the extracellular matrix (ECM), found in species ranging from Drosophila to humans. Cell adhesion proteins called integrins recognize and bind to this sequence, which is found within many matrix proteins, including fibronectin, fibrinogen, vitronectin, osteopontin, and several other adhesive extracellular matrix proteins.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_drugs:_Im–In">List of drugs: Im–In</a></td>
      <td>This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cerebroprotectant">Cerebroprotectant</a></td>
      <td>A cerebroprotectant (formerly known as a neuroprotectant) is a drug that is intended to protect the brain after the onset of acute ischemic stroke. As stroke is the second largest cause of death worldwide and a leading cause of adult disability, over 150 cerebroprotectants have been tested in clinical trials.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>MILLENNIUM PHARMACEUTICALS INC      Item 1A                RISK FACTORS THAT MAY AFFECT RESULTS       This Annual Report on Form 10-K and certain other <font color="blue">communications</font> made by us     contain forward-looking statements, including <font color="blue">statements about</font> our growth     and  future  operating results, <font color="blue">discovery</font> and <font color="blue">development</font> of products,     strategic  alliances  and <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>We often use the words “believe,” “anticipate,”     “plan,” “expect,” “intend,” “may,” “will” and similar <font color="blue">expressions</font> to help     identify forward-looking statements</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure investors</font> that our <font color="blue">assumptions</font> and <font color="blue"><font color="blue">expectations</font> will prove</font>     to have been correct</td>
    </tr>
    <tr>
      <td><font color="blue">Important </font><font color="blue">factors could</font> cause our actual results to     differ  <font color="blue">materially</font>  from those indicated or implied by forward-looking     statements</td>
    </tr>
    <tr>
      <td>Such factors that could cause or contribute to <font color="blue">such differences</font>     include  those  factors  discussed below</td>
    </tr>
    <tr>
      <td>We undertake <font color="blue">no intention</font> or     <font color="blue">obligation</font> to update or revise any forward-looking statements, whether as a     result of new information, <font color="blue">future events</font> or otherwise</td>
    </tr>
    <tr>
      <td>Regulatory Risks       Our business may be harmed if we do not obtain approval to market <font color="blue">VELCADE     </font>for <font color="blue">additional</font> <font color="blue">therapeutic</font> uses</td>
    </tr>
    <tr>
      <td>An important part of our strategy to grow our business is to market <font color="blue">VELCADE     </font>for <font color="blue">additional</font> <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>To do so, we will need to <font color="blue"><font color="blue">successfully</font> conduct</font>     <font color="blue"><font color="blue">clinical trial</font>s</font> and then apply for and obtain the <font color="blue"><font color="blue">appropriate</font> <font color="blue">regulatory</font></font>     approvals</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in our <font color="blue"><font color="blue">clinical trial</font>s</font>, or we experience a     delay in obtaining or are unable to obtain <font color="blue">authorizations</font> for <font color="blue">expanded uses</font>     of VELCADE, our <font color="blue">revenues may</font> not grow as expected and our business and     operating results will be harmed</td>
    </tr>
    <tr>
      <td>We may not be able to obtain approval in <font color="blue">additional</font> countries to market     <font color="blue">VELCADE     </font>  VELCADE is <font color="blue">currently approved</font> for marketing in the <font color="blue"><font color="blue">United States</font> </font>and more     than 60 other countries including the countries <font color="blue">of the European Union</font></td>
    </tr>
    <tr>
      <td>If we     are not able to obtain approval to market VELCADE in <font color="blue">additional</font> countries,     we will lose the <font color="blue">opportunity</font> to sell in those countries and will not be able     to earn potential milestone payments under our <font color="blue">agreement</font> with <font color="blue"><font color="blue">Ortho Biotech </font>    </font>or collect potential <font color="blue">distribution</font> fees on sales <font color="blue">of VELCADE </font>by <font color="blue"><font color="blue">Ortho Biotech </font>    </font>in those countries</td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       We may not be able to obtain <font color="blue">marketing approval</font> for products resulting from     our <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>The  products that we are developing require research and <font color="blue">development</font>,     extensive <font color="blue">pre<font color="blue">clinical studies</font></font> and <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue"><font color="blue">regulatory</font> approval</font>     prior to any <font color="blue"><font color="blue">commercial sale</font>s</font></td>
    </tr>
    <tr>
      <td>In some cases, the length of time that it     takes for us to achieve various <font color="blue"><font color="blue">regulatory</font> approval</font> milestones affects the     payments  that we are eligible to receive under our <font color="blue">strategic alliance</font>     <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>We may need to <font color="blue"><font color="blue">successfully</font> address</font> a number of <font color="blue"><font color="blue">technological</font> challenges</font> in     order to complete <font color="blue">development</font> of our products</td>
    </tr>
    <tr>
      <td>Moreover, these <font color="blue">products may</font>     not be <font color="blue">effective</font> in treating any disease or may prove to have undesirable or     unintended  side effects, toxicities or other <font color="blue">characteristics</font> that may     preclude our obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> or prevent or <font color="blue">limit commercial</font>     use</td>
    </tr>
    <tr>
      <td>For example, in January 2006, as part of our <font color="blue">portfolio review process</font>,     <font color="blue">based on</font> the <font color="blue">evaluation</font> of <font color="blue">recent clinical data</font> in the context of <font color="blue">additional</font>     <font color="blue">opportunities</font> in the pipeline, we decided to <font color="blue">discontinue</font> <font color="blue">development</font> at this     time  of  MLN2704 in its current form as well as MLN1202 in rheumatoid     arthritis</td>
    </tr>
    <tr>
      <td>Failure to gain approval for the products we are developing could have an     adverse material <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue"><font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font></font>, or if we experience     <font color="blue">unanticipated problems with</font> our <font color="blue">approved products</font>, our <font color="blue">products could</font> be     subject to <font color="blue">restrictions</font> or <font color="blue">withdrawal from</font> the market</td>
    </tr>
    <tr>
      <td>Any  product  for  which  we obtain <font color="blue">marketing approval</font>, along with the     <font color="blue">manufacturing</font>  processes,  post-approval clinical data and promotional     <font color="blue">activities</font> for <font color="blue">such product</font>, is subject to <font color="blue">continual review</font> and periodic     <font color="blue">inspections by</font> the FDA, and other <font color="blue"><font color="blue">regulatory</font> bodies</font></td>
    </tr>
    <tr>
      <td>Later <font color="blue">discovery</font> of     <font color="blue">previously</font>  unknown  problems  or  safety  <font color="blue">issues with</font> our products or     <font color="blue">manufacturing</font> processes, or failure to <font color="blue"><font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font></font>,     may result in <font color="blue">restrictions</font> on <font color="blue">such product</font>s or <font color="blue">manufacturing</font> processes,     withdrawal of the <font color="blue">products from</font> the market, the imposition of civil or     <font color="blue">criminal penalties</font> or a <font color="blue">refusal by</font> the FDA and other <font color="blue"><font color="blue">regulatory</font> bodies</font> to     approve  pending  <font color="blue">applications</font>  for <font color="blue">marketing approval</font> of new drugs or     <font color="blue">supplements</font>  to  approved  <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>As with any <font color="blue">recently approved</font>     <font color="blue">therapeutic</font> product, we expect that our knowledge of the <font color="blue">safety profile</font> for     VELCADE  will  expand after wider usage, and the <font color="blue">possibility</font> exists of     patients  receiving  VELCADE treatment experiencing unexpected or more     <font color="blue">frequently than</font> expected serious adverse events, which could have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>We are a party to <font color="blue"><font color="blue">collaboration</font>s</font> that <font color="blue">transfer <font color="blue">responsibility</font></font> for specified     <font color="blue">regulatory</font>  <font color="blue">requirements</font>,  <font color="blue">such as filing</font> and maintenance of marketing     <font color="blue">authorizations</font>  and  safety  reporting,  to  our <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>If our     <font color="blue"><font color="blue">collaborator</font>s</font>  do  not fulfill these <font color="blue">regulatory</font> <font color="blue">obligation</font>s, products,     including VELCADE or INTEGRILIN, could be <font color="blue">withdrawn from</font> the market, which     would have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">products may</font> be <font color="blue">based on</font> new <font color="blue">technologies</font> which may affect our     ability or the time we require to obtain <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>Products that result from our research and <font color="blue">development</font> programs may be based     on new <font color="blue">technologies</font>, such as proteasome inhibition, and new <font color="blue">therapeutic</font>     approaches that have not <font color="blue">been extensively tested</font> in humans</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font>     <font color="blue">requirements</font> governing these types of <font color="blue">products may</font> be more <font color="blue">rigorous than</font> for     <font color="blue">conventional products</font></td>
    </tr>
    <tr>
      <td>As a result, we may experience a longer <font color="blue">regulatory</font>     process in <font color="blue">connection</font> with any products that we develop <font color="blue">based on</font> these new     <font color="blue">technologies</font> or new <font color="blue">therapeutic</font> approaches</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________       Risks Relating to Our Business, Strategy and Industry       Our <font color="blue">revenues over</font> the <font color="blue">next several years will</font> be <font color="blue">materially</font> dependent on the     <font color="blue">commercial success</font> <font color="blue">of VELCADE </font>and <font color="blue">INTEGRILIN </font>      Our <font color="blue">revenues over</font> the <font color="blue">next several years will</font> be <font color="blue">materially</font> dependent on the     <font color="blue">commercial success</font> of our <font color="blue">two currently marketed products</font>: VELCADE and     <font color="blue"><font color="blue">INTEGRILIN </font>VELCADE </font>was <font color="blue">approved by</font> the <font color="blue">FDA in May </font>2003 and <font color="blue">commercially</font>     launched in the <font color="blue"><font color="blue">United States</font> </font>shortly after that date</td>
    </tr>
    <tr>
      <td>Marketing of <font color="blue">VELCADE     </font>outside the <font color="blue"><font color="blue">United States</font> </font>commenced in April 2004</td>
    </tr>
    <tr>
      <td><font color="blue">INTEGRILIN </font>has been on     the market in the <font color="blue"><font color="blue">United States</font> </font>since June 1998</td>
    </tr>
    <tr>
      <td>Marketing of <font color="blue">INTEGRILIN </font>    outside the <font color="blue"><font color="blue">United States</font> </font>commenced in mid-1999</td>
    </tr>
    <tr>
      <td>Our business plan contemplates obtaining <font color="blue">marketing authorization</font> to sell     VELCADE in many countries for the treatment of all <font color="blue">patients with multiple</font>     myeloma and both in the <font color="blue"><font color="blue">United States</font> </font>and abroad for other <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>We     will be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> if VELCADE does not receive <font color="blue">such approvals</font></td>
    </tr>
    <tr>
      <td>We will not achieve our business plan, and we may be forced to scale back     our <font color="blue">operations</font> and research and <font color="blue">development</font> programs, if we do not obtain     <font color="blue">regulatory</font>  approval  to  sell  VELCADE in <font color="blue">additional</font> countries or for     <font color="blue">additional</font> <font color="blue">therapeutic</font> uses or the sales <font color="blue">of VELCADE </font>or <font color="blue">INTEGRILIN </font>do not     meet our <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>We  face  substantial <font color="blue">competition</font>, and <font color="blue"><font color="blue">others may</font> discover</font>, develop or     <font color="blue"><font color="blue">commercialize</font> products</font> before or more <font color="blue"><font color="blue">successfully</font> than</font> we do</td>
    </tr>
    <tr>
      <td>The fields of <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue"><font color="blue">pharmaceutical</font>s</font> are <font color="blue">highly <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>of  our  <font color="blue">competitors</font>  are  <font color="blue">substantially</font> larger than we are, and these     <font color="blue">competitors</font> have <font color="blue">substantially</font> greater <font color="blue">capital resources</font>, research and     <font color="blue">development</font> staffs and <font color="blue">facilities</font> than we have</td>
    </tr>
    <tr>
      <td>Furthermore, many of our     <font color="blue">competitors</font> are more experienced than we are in drug research, <font color="blue">discovery</font>,     <font color="blue">development</font>  and <font color="blue">commercialization</font>, obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s and     product  <font color="blue">manufacturing</font> and marketing</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">competitors</font> may     discover, develop and <font color="blue">commercialize</font> <font color="blue">pharmaceutical</font> products before or in a     <font color="blue">shorter timeframe than</font> we do</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">competitors</font> may discover,     develop and <font color="blue"><font color="blue">commercialize</font> products</font> that make the products that we or our     <font color="blue"><font color="blue">collaborator</font>s</font> have developed or are seeking to develop and <font color="blue">commercialize</font>     non-<font color="blue">competitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>With respect to VELCADE, we face <font color="blue">competition</font> from Celgene’s Thalomid and its     <font color="blue">derivatives</font>, a treatment approved for <font color="blue">complications</font> associated with leprosy     which  is used broadly for <font color="blue">multiple myeloma</font> <font color="blue">based on</font> data published in     peer-reviewed <font color="blue">publications</font></td>
    </tr>
    <tr>
      <td>Celgene has filed a sNDA for Thalomid for the     treatment of <font color="blue">multiple myeloma</font> that was <font color="blue">accepted by</font> the FDA for review in     2005</td>
    </tr>
    <tr>
      <td>We also face <font color="blue">competition</font> <font color="blue">for VELCADE </font>from Celgene’s Revlimid which was     approved  by the <font color="blue">FDA in <font color="blue">December </font></font>2005 for the treatment of a subset of     patients with transfusion-dependent anemia</td>
    </tr>
    <tr>
      <td>Celgene is also developing     Revlimid for the treatment of <font color="blue">patients with multiple</font> myeloma and in early     2006 filed a sNDA with the FDA in this <font color="blue">indication</font> which could be approved in     2006</td>
    </tr>
    <tr>
      <td>We expect to see increased <font color="blue">competition</font> from Revlimid prior to approval     of this sNDA as Celgene <font color="blue">accelerates</font> its prelaunch <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We also face     <font color="blue">competition</font> <font color="blue">for VELCADE </font><font color="blue">from traditional chemotherapy treatments</font>, and there     are other <font color="blue">potentially <font color="blue">competitive</font> therapies</font> for VELCADE, including other     <font color="blue">proteasome <font color="blue">inhibitors</font></font>, that are in late-stage clinical <font color="blue">development</font> for the     treatment of <font color="blue">multiple myeloma</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">multiple myeloma</font> therapies in     <font color="blue">development</font>  may  reduce  the number of patients available for <font color="blue">VELCADE     </font><font color="blue">treatment through enrollment</font> of these patients in <font color="blue"><font color="blue">clinical trial</font>s</font> of these     <font color="blue">potentially competing products</font></td>
    </tr>
    <tr>
      <td>Due to the incidence and severity of <font color="blue">cardiovascular diseases</font>, the market for     <font color="blue">therapeutic</font> products that address these diseases is large, and we expect the     already intense <font color="blue">competition</font> in this field to increase</td>
    </tr>
    <tr>
      <td>The <font color="blue">most <font color="blue">significant</font></font>     <font color="blue">competitors</font>  for  SGP in marketing <font color="blue">INTEGRILIN </font>are major <font color="blue">pharmaceutical</font>     companies  and  <font color="blue">bio<font color="blue">technology</font></font> companies</td>
    </tr>
    <tr>
      <td>The <font color="blue">two products</font> that compete     <font color="blue">directly with</font> <font color="blue">INTEGRILIN </font>in the GP IIb-IIIa <font color="blue">inhibitor market</font> segment are     ReoPro® (abciximab), which is produced by Johnson &amp; Johnson       18     ______________________________________________________________________       and  sold  by  Johnson &amp;  Johnson  and  Eli  Lilly  and  Company,  and     Aggrastat® (tirofiban HCl), which is produced and sold by Merck &amp; Co, Inc</td>
    </tr>
    <tr>
      <td>outside of the <font color="blue"><font color="blue">United States</font> </font>and by Guilford Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue"><font color="blue">competitive</font> factors</font> that <font color="blue">could negatively affect</font> <font color="blue">INTEGRILIN </font>include:       ·        expanded  use  of  heparin  <font color="blue">replacement</font>  therapies,  such  as     Angiomax® (<font color="blue">bivalirudin</font>),  which  is produced and sold by The Medicines     Company;       ·        changing  treatment  practices  for  <font color="blue">PCI and ACS </font><font color="blue">based on</font> new     <font color="blue">technologies</font>, including the use of drug-coated stents;       ·       <font color="blue">increased use</font> of another class of anti-platelet drugs known as ADP     <font color="blue">inhibitors</font> in <font color="blue">patients whose symptoms</font> make <font color="blue">them potential <font color="blue">candidates</font></font> for     <font color="blue">treatment with</font> INTEGRILIN; and       ·       SGP’s <font color="blue">inability</font> to complete <font color="blue"><font color="blue">clinical trial</font>s</font> and develop data to     promote <font color="blue">increased use</font> of <font color="blue">INTEGRILIN </font>in its current <font color="blue"><font color="blue">indication</font>s</font> as well as in     new <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>Sales of <font color="blue">INTEGRILIN </font>and possibly VELCADE in particular reporting periods may     be <font color="blue">affected by</font> <font color="blue">fluctuations</font> in inventory, <font color="blue">allowances</font> and <font color="blue">buying patterns</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of <font color="blue">INTEGRILIN </font>domestic <font color="blue">pharmaceutical</font> sales is made by     SGP to major drug <font color="blue">wholesalers</font></td>
    </tr>
    <tr>
      <td>These sales are <font color="blue">affected by</font> <font color="blue">fluctuations</font> in     the <font color="blue">buying patterns</font> of these <font color="blue">wholesalers</font> and the <font color="blue">corresponding</font> changes in     inventory  levels  maintained  by them</td>
    </tr>
    <tr>
      <td><font color="blue">Inventory </font>levels held by these     <font color="blue">wholesalers</font> may fluctuate <font color="blue">significant</font>ly from quarter to quarter</td>
    </tr>
    <tr>
      <td>If these     <font color="blue">wholesalers</font> build inventory levels excessively in any quarter, sales to the     <font color="blue">wholesalers</font> in future quarters may unexpectedly decrease notwithstanding     <font color="blue">steady prescriber demand</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because SGP </font><font color="blue">commercialize</font>s <font color="blue">INTEGRILIN </font>and manages     product <font color="blue">distribution</font>, we have limited insight into or control over forces     <font color="blue">affecting</font>  changes  in  <font color="blue">distributor</font>  inventory levels</td>
    </tr>
    <tr>
      <td>If SGP does not     <font color="blue"><font color="blue">appropriate</font>ly manage</font> this <font color="blue">distribution</font>, SGP may not realize <font color="blue">sales goals</font> for     the product and <font color="blue">could reduce</font> the <font color="blue">royalty revenue</font> we recognize and thus     <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>We distribute <font color="blue">VELCADE in the US </font>through a sole-source <font color="blue">distribution</font> model,     where we <font color="blue">sell directly</font> to a <font color="blue">third party</font> who in turn <font color="blue">distributes</font> to the     <font color="blue">wholesaler base</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our VELCADE </font><font color="blue">product inventory levels may fluctuate from</font>     time to time <font color="blue">depending on</font> the <font color="blue">consistency</font> of the <font color="blue">distribution</font> logistics of     this <font color="blue">arrangement</font> and the <font color="blue">buying patterns</font> of these <font color="blue">wholesalers</font></td>
    </tr>
    <tr>
      <td>Additionally,  we  make  <font color="blue">provisions at</font> the time of sale <font color="blue">of VELCADE </font>for     <font color="blue">discounts</font>, rebates, product returns and other <font color="blue">allowances</font> <font color="blue">based on</font> historical     experience updated for changes in facts and <font color="blue">circumstances</font>, as <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>To the extent these <font color="blue">allowances</font> are incorrect, we may need to adjust our     estimates, which could have a material <font color="blue">impact on</font> the timing and actual     amount of revenue we are able to recognize from these sales</td>
    </tr>
    <tr>
      <td>Because our research and <font color="blue">development</font> projects are <font color="blue">based on</font> new <font color="blue">technologies</font>     and new <font color="blue">therapeutic</font> approaches that have not <font color="blue">been extensively tested</font> in     humans,  it  is possible that our <font color="blue">discovery</font> process will not result in     <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td>The  process  of  <font color="blue">discovering</font>  <font color="blue">drugs based upon genomics</font> and other new     <font color="blue">technologies</font> is new and <font color="blue">evolving rapidly</font></td>
    </tr>
    <tr>
      <td>We focus a portion of our research     on diseases that may be linked to a number of genes working in <font color="blue">combination</font>     or  to  novel  targets</td>
    </tr>
    <tr>
      <td>Both we and the <font color="blue">general scientific</font> and medical     <font color="blue">communities</font> have only a limited understanding of the role that <font color="blue">genes play</font> in     these diseases</td>
    </tr>
    <tr>
      <td>To date, we have not <font color="blue">commercialize</font>d any <font color="blue">products discovered</font>     through our <font color="blue">genomics research</font>, and we may not be successful in doing so in     the future</td>
    </tr>
    <tr>
      <td>In addition, relatively few products <font color="blue">based on</font> gene <font color="blue">discoveries</font>     have  been developed and <font color="blue">commercialize</font>d by others</td>
    </tr>
    <tr>
      <td>Rapid <font color="blue">technological</font>     <font color="blue">development</font> by us or <font color="blue">others may</font> result in compounds, products or processes     <font color="blue">becoming obsolete</font> before we recover our <font color="blue">development</font> expenses</td>
    </tr>
    <tr>
      <td>Further,       19     ______________________________________________________________________       <font color="blue">manufacturing</font> costs or products <font color="blue">based on</font> these new <font color="blue">technologies</font> may make     <font color="blue">products uneconomical</font> to <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">clinical trial</font>s</font> are <font color="blue">unsuccessful</font>, or if they experience <font color="blue">significant</font>     delays, our ability to <font color="blue"><font color="blue">commercialize</font> products</font> will be impaired</td>
    </tr>
    <tr>
      <td>We must provide the FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> with preclinical     and clinical data <font color="blue">demonstrating</font> that our products are safe and <font color="blue">effective</font>     before they can be approved for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">development</font>,     including <font color="blue">preclinical testing</font>, is a long, expensive and <font color="blue">uncertain process</font></td>
    </tr>
    <tr>
      <td>It may take <font color="blue">us several years</font> to complete our testing, and failure can occur     at any stage of testing</td>
    </tr>
    <tr>
      <td>Interim results of preclinical or <font color="blue">clinical studies</font>     do not <font color="blue">necessarily predict</font> their final results, and acceptable results in     early  studies  might not be seen in <font color="blue">later studies</font></td>
    </tr>
    <tr>
      <td>Any preclinical or     clinical  test  may  fail  to produce results satisfactory to the FDA     Preclinical and clinical data can be interpreted in <font color="blue">different</font> ways, which     <font color="blue">could delay</font>, limit or prevent <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>Negative or <font color="blue">inconclusive</font>     results from a <font color="blue">preclinical study</font> or <font color="blue">clinical trial</font>, adverse medical events     during a <font color="blue">clinical trial</font> or safety issues resulting from products of the same     class  of drug could cause a <font color="blue">preclinical study</font> or <font color="blue">clinical trial</font> to be     repeated or a program to be terminated, even if other studies or trials     relating to the program are successful</td>
    </tr>
    <tr>
      <td>For example, in <font color="blue">December </font>2003 we     decided to <font color="blue">stop further accrual</font> to a phase II trial examining VELCADE in     colorectal cancer because interim findings produced results that did not     meet the pre-specified efficacy criteria for <font color="blue">continuation</font> of study accrual</td>
    </tr>
    <tr>
      <td>We may not complete our planned preclinical or <font color="blue"><font color="blue">clinical trial</font>s</font> on schedule     or at all</td>
    </tr>
    <tr>
      <td>We may not be able to confirm the safety and efficacy of our     <font color="blue">potential drugs</font> in long-term <font color="blue"><font color="blue">clinical trial</font>s</font>, which may result in a delay or     failure to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We may have <font color="blue"><font color="blue">difficult</font>y</font> obtaining a     sufficient number of <font color="blue"><font color="blue">appropriate</font> patients</font> or <font color="blue">clinical support</font> to conduct our     <font color="blue"><font color="blue">clinical trial</font>s</font> as planned</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">additional</font> events <font color="blue">could delay</font> the     <font color="blue">completion</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font>, including <font color="blue"><font color="blue">conditions</font> imposed on us by</font> the     FDA or foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> regarding the scope or design of our     <font color="blue"><font color="blue">clinical trial</font>s</font>, lower than anticipated retention rates for patients in our     <font color="blue"><font color="blue">clinical trial</font>s</font>, insufficient supply or deficient quality of our product     <font color="blue">candidates</font> or other <font color="blue">materials <font color="blue">necessary</font></font> to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font> or     the  failure  of our <font color="blue">third party</font> contractors to <font color="blue">comply with</font> <font color="blue">regulatory</font>     <font color="blue">requirements</font> or <font color="blue">otherwise meet</font> their contractual <font color="blue">obligation</font>s to us in a     <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>As a result, we may have to expend substantial <font color="blue">additional</font>     funds  to  obtain  access  to  resources  or delay or modify our plans     <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> costs will increase if we experience     delays in testing or approvals</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">clinical trial</font> delays could     allow our <font color="blue">competitors</font> to <font color="blue">bring products</font> to market before we do and impair     our ability to <font color="blue">commercialize</font> our products or <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">third parties</font> on which</font> we rely for <font color="blue"><font color="blue">clinical trial</font>s</font> do not perform as     <font color="blue">contractually</font>  required  or as we expect, we may not be able to obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> for or <font color="blue">commercialize</font> our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on independent clinical investigators</font> and, in some cases, contract     <font color="blue">research <font color="blue">organizations</font></font> and other <font color="blue">third party</font> service providers to conduct     the <font color="blue"><font color="blue">clinical trial</font>s</font> of our product <font color="blue">candidates</font> and expect to continue to do     so</td>
    </tr>
    <tr>
      <td>We  <font color="blue">rely <font color="blue">heavily on</font></font> these parties for <font color="blue">successful execution</font> of our     <font color="blue"><font color="blue">clinical trial</font>s</font>, but we do not control many aspects of their <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Nonetheless, we are responsible for <font color="blue">confirming</font> that each of our clinical     trials is conducted in <font color="blue">accordance with</font> the <font color="blue">general investigational</font> plan and     protocol</td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> these <font color="blue">third parties</font> that we do not control does     not <font color="blue">relieve us</font> of our <font color="blue">responsibility</font> to <font color="blue">comply with</font> the <font color="blue">regulations</font> and     standards of the FDA relating to good <font color="blue">clinical practices</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font>     not complete <font color="blue">activities</font> on schedule or may not conduct our <font color="blue"><font color="blue">clinical trial</font>s</font>     in <font color="blue">accordance with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> or the <font color="blue">applicable trials</font> plans     and  protocols</td>
    </tr>
    <tr>
      <td>The failure of these <font color="blue">third parties</font> to carry out their     <font color="blue">obligation</font>s  could  delay  or  prevent  the  <font color="blue">development</font>, approval and     <font color="blue">commercialization</font> of our product <font color="blue">candidates</font> or result in <font color="blue">enforcement action</font>     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       <font color="blue">Because  </font>many  of the products that we are developing are <font color="blue">based on</font> new     <font color="blue">technologies</font> and <font color="blue">therapeutic</font> approaches, the <font color="blue">market may</font> not be receptive to     these <font color="blue">products upon</font> their <font color="blue">introduction</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">commercial success</font> of any of our products for which we may obtain     <font color="blue">marketing approval</font> from the FDA or other <font color="blue">regulatory</font> <font color="blue">authorities</font> will depend     upon their <font color="blue"><font color="blue">acceptance</font> by</font> the <font color="blue">medical community</font> and <font color="blue">third party</font> payors as     clinically useful, cost-<font color="blue">effective</font> and safe</td>
    </tr>
    <tr>
      <td>Many of the products that we are     developing are based upon new <font color="blue">technologies</font> or <font color="blue">therapeutic</font> approaches</td>
    </tr>
    <tr>
      <td>As a     result, it may be more <font color="blue">difficult</font> for us to achieve market <font color="blue">acceptance</font> of our     products, <font color="blue">particularly</font> the first products that we introduce to the market     <font color="blue">based on</font> new <font color="blue">technologies</font> and <font color="blue">therapeutic</font> approaches</td>
    </tr>
    <tr>
      <td>Our efforts to educate     the <font color="blue">medical community</font> on these <font color="blue">potentially unique approaches may</font> require     <font color="blue">greater resources than would</font> be typically required for products <font color="blue">based on</font>     conventional <font color="blue">technologies</font> or <font color="blue">therapeutic</font> approaches</td>
    </tr>
    <tr>
      <td>The safety, efficacy,     convenience  and  cost-<font color="blue">effective</font>ness  of  our  <font color="blue"><font color="blue">products as</font> compared</font> to     <font color="blue">competitive</font> <font color="blue">products will</font> also affect market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Because of the high demand for <font color="blue">talented personnel within</font> our industry, we     could experience <font color="blue">difficult</font>ies in <font color="blue">recruiting employees <font color="blue">necessary</font></font> for our     success and growth</td>
    </tr>
    <tr>
      <td>Because <font color="blue">competition</font> for <font color="blue">talented employees within</font> our industry is fierce, we     may  not  be successful in hiring, retaining or <font color="blue">promptly replacing key</font>     <font color="blue">management</font>,  sales,  marketing and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>Any failure to     <font color="blue">expeditiously fill</font> our needs for <font color="blue">key personnel could</font> have a material adverse     effect on our business</td>
    </tr>
    <tr>
      <td>Risks Relating to Our Financial Results and Need for Financing       We have incurred substantial losses and expect to continue to <font color="blue">incur losses</font></td>
    </tr>
    <tr>
      <td>We will not be <font color="blue">successful unless</font> we reverse this trend</td>
    </tr>
    <tr>
      <td>We  have  incurred  net  losses  of  dlra198dtta2 million for the year ended     <font color="blue">December </font>31, 2005, dlra252dtta3 million for the year ended <font color="blue">December </font>31, 2004 and     dlra483dtta7 million for the year ended <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td>We expect to continue     to  incur substantial operating losses in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>Prior to our     <font color="blue">acquisition</font> of COR, <font color="blue">substantially</font> all of our revenues resulted from payments     from <font color="blue"><font color="blue">collaborator</font>s</font>, and not from the sale of products</td>
    </tr>
    <tr>
      <td>We expect to continue to incur <font color="blue">significant</font> expenses in <font color="blue">connection</font> with our     research and <font color="blue">development</font> programs and <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>As a     result, we will need to generate <font color="blue">significant</font> revenues to help fund these     costs and achieve positive net income</td>
    </tr>
    <tr>
      <td>Our ability to achieve positive net     <font color="blue">income would</font> be <font color="blue"><font color="blue">adversely</font> impacted</font> if our acquired <font color="blue">intangible assets</font> and     goodwill, primarily resulting from our <font color="blue">acquisition</font> of COR, <font color="blue">became impaired</font>     as  a  result  of <font color="blue">reduced market capitalization</font> or <font color="blue">product failures</font> or     <font color="blue">withdrawals</font></td>
    </tr>
    <tr>
      <td>We cannot be <font color="blue">certain whether</font> or when we <font color="blue">will become profitable</font>     because of the <font color="blue">significant</font> uncertainties with respect to our ability to     <font color="blue">successfully</font>  develop  products and <font color="blue">generate <font color="blue">revenues from</font></font> the sale of     approved  products  and  from  existing and <font color="blue">potential future strategic</font>     alliances</td>
    </tr>
    <tr>
      <td>We may need <font color="blue">additional</font> financing, which may be <font color="blue">difficult</font> to obtain</td>
    </tr>
    <tr>
      <td>Our     failure to obtain <font color="blue"><font color="blue">necessary</font> financing</font> or doing so <font color="blue">on unattractive terms</font>     could <font color="blue"><font color="blue">adversely</font> affect</font> our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We will require substantial funds to <font color="blue">conduct research</font> and <font color="blue">development</font>,     including <font color="blue">preclinical testing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>We  will also require substantial funds to meet our <font color="blue">obligation</font>s to our     <font color="blue"><font color="blue">collaborator</font>s</font>,  <font color="blue">manufacture</font>  and <font color="blue">market products</font> that are approved for     <font color="blue">commercial sale</font>, including VELCADE, and meet our debt service <font color="blue">obligation</font>s</td>
    </tr>
    <tr>
      <td>We may also require <font color="blue">additional</font> financing to execute on product in-licensing     or <font color="blue">acquisition</font> <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">financing may</font> not be available when     we need it or may not be <font color="blue">available on</font> favorable terms</td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">adequate funding on</font> a <font color="blue">timely basis</font>, we may have     to delay or curtail our research and <font color="blue">development</font> programs, our product     <font color="blue">commercialization</font> <font color="blue">activities</font> or our in-licensing or <font color="blue">acquisition</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We could be required to seek funds through <font color="blue">arrangement</font>s with <font color="blue"><font color="blue">collaborator</font>s</font>     or       21     ______________________________________________________________________       others that may require us to <font color="blue">relinquish rights</font> to specified <font color="blue">technologies</font>,     product <font color="blue">candidates</font> or <font color="blue">products which</font> we <font color="blue">would otherwise pursue on</font> our own</td>
    </tr>
    <tr>
      <td>Our <font color="blue">indebtedness</font> and debt service <font color="blue">obligation</font>s may <font color="blue"><font color="blue">adversely</font> affect</font> our cash     flow and <font color="blue">otherwise negatively affect</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>At <font color="blue">December </font>31, 2005, we had <font color="blue">approximately</font> dlra105dtta5 million of outstanding     <font color="blue">convertible debt</font>, of which dlra5dtta9 million matures in 2006 and dlra99dtta6 million     matures in 2007 and dlra80dtta4 million of capital lease <font color="blue">obligation</font>s</td>
    </tr>
    <tr>
      <td>During each     of the <font color="blue">last five years</font>, our earnings were insufficient to cover our fixed     charges</td>
    </tr>
    <tr>
      <td>We will be required to make <font color="blue">interest payments on</font> our outstanding     convertible notes totaling <font color="blue">approximately</font> dlra8dtta2 million over the next two     years</td>
    </tr>
    <tr>
      <td>We will be required to make <font color="blue">interest payments totaling <font color="blue">approximately</font></font>     dlra7dtta5 million over the <font color="blue">next three years on</font> our <font color="blue">capital leases</font></td>
    </tr>
    <tr>
      <td>We may in the future incur <font color="blue">additional</font> <font color="blue">indebtedness</font>, including long-term     debt, credit lines and property and <font color="blue">equipment financings</font> to <font color="blue">finance capital</font>     <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>We intend to satisfy our current and <font color="blue">future debt service</font>     <font color="blue">obligation</font>s from cash generated by our <font color="blue">operations</font>, our <font color="blue">existing cash</font> and     <font color="blue">investments</font> and, in the case of principal payments at maturity, funds from     <font color="blue">external sources</font></td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient funds</font> and we may be unable to     arrange  for <font color="blue">additional</font> financing to satisfy our principal or interest     payment <font color="blue">obligation</font>s when those <font color="blue">obligation</font>s become due</td>
    </tr>
    <tr>
      <td>Funds <font color="blue">from external</font>     <font color="blue">sources may</font> not be <font color="blue">available on</font> acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">indebtedness</font> could have <font color="blue">significant</font> <font color="blue">additional</font> negative consequences,     including:       ·        increasing  our <font color="blue">vulnerability</font> to <font color="blue">general adverse economic</font> and     industry <font color="blue">conditions</font>;       ·       limiting our ability to obtain <font color="blue">additional</font> financing;       ·       requiring the <font color="blue">dedication</font> of a substantial portion of our <font color="blue">cash flow</font>     from <font color="blue">operations</font> to service our <font color="blue">indebtedness</font>, thereby reducing the amount of     our expected <font color="blue">cash flow</font> available for other purposes, including capital     <font color="blue">expenditures</font> and research and <font color="blue">development</font>;       ·       limiting our <font color="blue">flexibility</font> in planning for, or reacting to, changes in     our business and the industry in which we compete; and       ·       <font color="blue">placing us at</font> a <font color="blue">possible <font color="blue">competitive</font> disadvantage</font> to <font color="blue">less leveraged</font>     <font color="blue">competitors</font> and <font color="blue">competitors</font> that have <font color="blue">better access</font> to <font color="blue">capital resources</font></td>
    </tr>
    <tr>
      <td>If we do not achieve the anticipated benefits of our <font color="blue"><font color="blue">restructuring</font> efforts</font>,     or if the costs of our <font color="blue"><font color="blue">restructuring</font> efforts</font> exceed anticipated levels, our     business could be harmed</td>
    </tr>
    <tr>
      <td>We  <font color="blue">recorded <font color="blue">restructuring</font> charges</font> of dlra77dtta1 million for the year ended     <font color="blue">December </font>31, 2005, dlra38dtta0 million for the year ended <font color="blue">December </font>31, 2004 and     dlra191dtta0 million for the year ended <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2002 and     June 2003, we took steps as part of our 2003 <font color="blue">restructuring</font> plan to focus our     resources on <font color="blue">development</font> and <font color="blue">commercialization</font> of product <font color="blue">opportunities</font> and     achieving our goal of <font color="blue">becoming profitable</font> in the future</td>
    </tr>
    <tr>
      <td>We may not achieve     the <font color="blue">cost savings</font> anticipated from the <font color="blue"><font color="blue">restructuring</font>s</font> because <font color="blue">such savings</font>     are <font color="blue">difficult</font> to predict and <font color="blue">speculative</font> in nature</td>
    </tr>
    <tr>
      <td><font color="blue">On <font color="blue">September </font></font>1, 2005, we     <font color="blue">transferred exclusive</font> US <font color="blue">commercialization</font> and <font color="blue">development</font> rights of     <font color="blue">INTEGRILIN </font>to SGP and on October 26, 2005, we announced <font color="blue">additional</font> efforts     to refine our strategy including a substantial reduction of our <font color="blue">inflammation</font>     <font color="blue">discovery</font> programs</td>
    </tr>
    <tr>
      <td>As a result of these efforts, we expect to reduce total     research and <font color="blue">development</font> and selling, general and <font color="blue">administration</font> expenses by     <font color="blue">approximately</font> 19 percent in 2006 from 2005 and 30 percent in 2006 from 2004</td>
    </tr>
    <tr>
      <td>We  expect to record <font color="blue">additional</font> <font color="blue">restructuring</font> charges of between dlra25dtta0     million to dlra30dtta0 million in 2006</td>
    </tr>
    <tr>
      <td>We may not achieve our estimated expense     <font color="blue">reductions</font> because <font color="blue">such savings</font> are <font color="blue">difficult</font> to predict and <font color="blue">speculative</font> in     nature</td>
    </tr>
    <tr>
      <td>While  we  believe our <font color="blue">restructuring</font> estimates to be reasonable, it is     possible that the <font color="blue">actual charges will exceed</font> the <font color="blue">ranges discussed</font> above</td>
    </tr>
    <tr>
      <td>For     example, we may not be able to lease <font color="blue">facilities</font> that we have closed or plan     to close in <font color="blue">connection</font> with the <font color="blue">restructuring</font> as quickly or on as favorable     terms as we anticipated</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       Risks Relating to Collaborators       We  depend  <font color="blue">significant</font>ly  on  our  <font color="blue"><font color="blue">collaborator</font>s</font>  to  work with us to     <font color="blue">commercialize</font> and develop products including VELCADE and <font color="blue">INTEGRILIN </font>      Outside of the <font color="blue">United States</font>, we <font color="blue">commercialize</font> VELCADE through an alliance     with Ortho Biotech</td>
    </tr>
    <tr>
      <td><font color="blue">On <font color="blue">September </font></font>1, 2005, we <font color="blue">transferred exclusive</font> US     <font color="blue">commercialization</font> and <font color="blue">development</font> rights of <font color="blue">INTEGRILIN </font>to SGP and SGP is     <font color="blue">solely responsible</font> for the <font color="blue">commercialization</font> and <font color="blue">development</font> of <font color="blue">INTEGRILIN </font>    outside of Europe</td>
    </tr>
    <tr>
      <td>We conduct substantial <font color="blue">discovery</font> and <font color="blue">development</font> <font color="blue">activities</font>     through <font color="blue">strategic alliance</font>s, including with <font color="blue">Ortho Biotech </font>for the ongoing     <font color="blue">development</font> <font color="blue">of VELCADE </font>We expect to enter into <font color="blue">additional</font> alliances in the     future, especially in <font color="blue">connection</font> with product <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>The success     of  our <font color="blue">alliances depends <font color="blue">heavily on</font></font> the efforts and <font color="blue">activities</font> of our     <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>Each of our <font color="blue"><font color="blue">collaborator</font>s</font> has <font color="blue">significant</font> <font color="blue">discretion</font> in determining the     efforts and resources that it will apply to the alliance and the degree to     which it <font color="blue">shares financial</font> and <font color="blue">product sales</font> and inventory information</td>
    </tr>
    <tr>
      <td>Our     existing and any <font color="blue">future alliances may</font> not be <font color="blue">scientifically</font> or <font color="blue">commercially</font>     successful</td>
    </tr>
    <tr>
      <td>The risks that we face in <font color="blue">connection</font> with these existing and any future     alliances include the following:       ·       All of our <font color="blue">strategic alliance</font> <font color="blue">agreement</font>s are for fixed terms and are     subject to <font color="blue">termination</font> under various <font color="blue">circumstances</font>, including, in many     cases, such as in our <font color="blue">collaboration</font> with Ortho Biotech, without cause</td>
    </tr>
    <tr>
      <td>·       Our <font color="blue"><font color="blue">collaborator</font>s</font> may change the focus of their <font color="blue">development</font> and     <font color="blue">commercialization</font>  efforts</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>and <font color="blue">bio<font color="blue">technology</font></font> companies     <font color="blue">historically</font> have re-evaluated their <font color="blue">development</font> and <font color="blue">commercialization</font>     priorities following mergers and <font color="blue">consolidations</font>, which have been common in     recent years in these <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>The ability of some of our products,     including VELCADE and INTEGRILIN, to reach their potential could be limited     if our <font color="blue"><font color="blue">collaborator</font>s</font> decrease or fail to increase marketing or spending     efforts related to <font color="blue">such product</font>s</td>
    </tr>
    <tr>
      <td>·       We expect to rely on our <font color="blue"><font color="blue">collaborator</font>s</font> to <font color="blue">manufacture</font> many products     <font color="blue">covered by</font> our alliances</td>
    </tr>
    <tr>
      <td>·       In our <font color="blue">strategic alliance</font> <font color="blue">agreement</font>s, we <font color="blue">generally agree</font> not to     <font color="blue">conduct specified types</font> of research and <font color="blue">development</font> in the field that is the     subject of the alliance</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s may have the effect of limiting     the areas of research and <font color="blue">development</font> that we may pursue, either alone or in     <font color="blue">collaboration</font> with <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>·       Our <font color="blue"><font color="blue">collaborator</font>s</font> may develop and <font color="blue">commercialize</font>, either alone or     with others, products that are similar to or <font color="blue"><font color="blue">competitive</font> with</font> the products     that are the subject of the <font color="blue">alliance with us</font></td>
    </tr>
    <tr>
      <td>·        Our  <font color="blue"><font color="blue">collaborator</font>s</font>  may  not  properly maintain or defend our     <font color="blue">intellectual property</font> rights or may use our <font color="blue">proprietary</font> information in such     a way as to expose us to <font color="blue">potential <font color="blue">litigation</font></font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">substantially</font> dependent on SGP for future revenues related to     <font color="blue">INTEGRILIN </font>      Under  the  terms  of  our  revised <font color="blue">agreement</font> with SGP <font color="blue">effective</font> as of     <font color="blue">September </font>1, 2005, SGP <font color="blue">will pay us royalties</font>  <font color="blue">based on</font> net <font color="blue">product sales</font> of     <font color="blue">INTEGRILIN </font>In 2006 and 2007, minimum royalty payments for <font color="blue">each year</font> are set     at dlra85dtta4 million, with some <font color="blue">conditions</font> that <font color="blue">could reduce</font> these minimums</td>
    </tr>
    <tr>
      <td>If     SGP’s <font color="blue">INTEGRILIN </font>sales after 2007 are less than expected, we will receive     less <font color="blue">royalty revenue</font> than we expect, <font color="blue">which would</font> have a material adverse     effect on our ability to fund other parts of our business</td>
    </tr>
    <tr>
      <td>We may not be successful in establishing <font color="blue">additional</font> <font color="blue">strategic alliance</font>s,     which  could <font color="blue"><font color="blue">adversely</font> affect</font> our ability to develop and <font color="blue">commercialize</font>     products</td>
    </tr>
    <tr>
      <td>An important element of our business strategy is <font color="blue">entering into strategic</font>     alliances for the <font color="blue">development</font> and <font color="blue">commercialization</font> of <font color="blue">selected products</font></td>
    </tr>
    <tr>
      <td>In     some instances, if we are <font color="blue">unsuccessful</font> in reaching an <font color="blue">agreement</font> with a     <font color="blue">suitable <font color="blue">collaborator</font></font>, we may fail to meet all of our business <font color="blue">objectives</font>     for the applicable       23     ______________________________________________________________________       product or program</td>
    </tr>
    <tr>
      <td>We face <font color="blue">significant</font> <font color="blue">competition</font> in <font color="blue">seeking <font color="blue">appropriate</font></font>     <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>Moreover,  these  alliance <font color="blue">arrangement</font>s are complex to     negotiate and time-consuming to document</td>
    </tr>
    <tr>
      <td>We may not be successful in our     efforts to establish <font color="blue">additional</font> <font color="blue">strategic alliance</font>s or other <font color="blue">alternative</font>     <font color="blue">arrangement</font>s</td>
    </tr>
    <tr>
      <td>The terms of any <font color="blue">additional</font> <font color="blue">strategic alliance</font>s or other     <font color="blue">arrangement</font>s that we <font color="blue">establish may</font> not be favorable to us</td>
    </tr>
    <tr>
      <td>Moreover, such     <font color="blue">strategic alliance</font>s or other <font color="blue">arrangement</font>s may not be successful</td>
    </tr>
    <tr>
      <td>Risks Relating to Intellectual Property       If we are unable to obtain <font color="blue">patent protection</font> for our <font color="blue">discoveries</font>, the value     of our <font color="blue">technology</font> and <font color="blue">products will</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>If we infringe     patent or other <font color="blue">intellectual property</font> rights of <font color="blue">third parties</font>, we may not be     able to develop and <font color="blue">commercialize</font> our products or the cost of doing so may     increase</td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent positions</font>, and those of other <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     companies, are <font color="blue">generally uncertain</font> and involve complex legal, scientific and     factual questions</td>
    </tr>
    <tr>
      <td>Our ability to develop and <font color="blue"><font color="blue">commercialize</font> products</font> depends     in <font color="blue">significant</font> part on our ability to:       ·       obtain and maintain patents;       ·       obtain licenses to the <font color="blue">proprietary</font> rights of others on <font color="blue">commercially</font>     <font color="blue">reasonable terms</font>;       ·       operate <font color="blue">without infringing upon</font> the <font color="blue">proprietary</font> rights of others;       ·       <font color="blue">prevent others from infringing on</font> our <font color="blue">proprietary</font> rights; and       ·       <font color="blue">protect trade secrets</font></td>
    </tr>
    <tr>
      <td>There is <font color="blue">significant</font> <font color="blue">uncertainty</font> about the validity and <font color="blue">permissible scope</font> of     patents in our industry, which may make it <font color="blue">difficult</font> for us to obtain patent     protection for our <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>The validity and <font color="blue">permissible scope</font> of patent claims in the <font color="blue">pharmaceutical</font>     and <font color="blue">bio<font color="blue">technology</font></font> fields, including the genomics field, involve important     <font color="blue">unresolved legal principles</font> and are the subject of <font color="blue">public policy debate</font> in     the <font color="blue"><font color="blue">United States</font> </font>and abroad</td>
    </tr>
    <tr>
      <td>For example, there is <font color="blue">significant</font> <font color="blue">uncertainty</font>     both in the <font color="blue"><font color="blue">United States</font> </font>and abroad regarding the patentability of gene     sequences  in  the  absence of functional data and the scope of patent     <font color="blue">protection available</font> for full-length genes and <font color="blue">partial <font color="blue">gene sequences</font></font></td>
    </tr>
    <tr>
      <td>Moreover, some groups have made <font color="blue">particular <font color="blue">gene sequences</font> available</font> in     <font color="blue">publicly accessible databases</font></td>
    </tr>
    <tr>
      <td>These and other <font color="blue">disclosures may <font color="blue">adversely</font></font>     affect our ability to obtain <font color="blue">patent protection</font> for <font color="blue">gene sequences</font> claimed by     us in patent <font color="blue">applications</font> that we <font color="blue">file subsequent</font> to <font color="blue">such disclosures</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>is also some <font color="blue"><font color="blue">uncertainty</font> as</font> to <font color="blue">whether human clinical data will</font> be required     for issuance of patents for human <font color="blue">therapeutic</font>s</td>
    </tr>
    <tr>
      <td>If such data are required,     our  ability to obtain <font color="blue">patent protection</font> could be delayed or otherwise     <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> own or <font color="blue">control patents</font> or patent <font color="blue">applications</font> and require     us  to  seek  licenses,  which  could  increase  our  <font color="blue">development</font>  and     <font color="blue">commercialization</font> costs, or <font color="blue">prevent us from</font> developing or marketing our     products</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">rights under</font> some patents or patent <font color="blue">applications</font> related to     some of our existing and <font color="blue">proposed products</font> or processes</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font>     own or control these patents and patent <font color="blue">applications</font> in the <font color="blue"><font color="blue">United States</font> </font>    and abroad</td>
    </tr>
    <tr>
      <td>Therefore, in some cases, such as those described below, in     order to develop, <font color="blue">manufacture</font>, sell or import some of our existing and     <font color="blue">proposed products</font> or processes, we or our <font color="blue"><font color="blue">collaborator</font>s</font> may choose to seek,     or be required to seek, licenses under <font color="blue">third party</font> patents issued in the     <font color="blue"><font color="blue">United States</font> </font>and abroad, or those that might issue from <font color="blue"><font color="blue">United States</font> </font>and     foreign patent <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>In such event, we would be required to pay     <font color="blue">license fees</font> or royalties or both to the licensor</td>
    </tr>
    <tr>
      <td>If licenses are not     available to us on acceptable terms, we or our <font color="blue"><font color="blue">collaborator</font>s</font> may not be able     to develop, <font color="blue">manufacture</font>, sell or import these products or processes</td>
    </tr>
    <tr>
      <td>Our  MLN02  and  MLN1202  product  <font color="blue">candidates</font> are <font color="blue">humanized monoclonal</font>     <font color="blue">antibodies</font></td>
    </tr>
    <tr>
      <td>We are aware of <font color="blue">third party</font> patents and patent <font color="blue">applications</font> that     relate to humanized or modified <font color="blue">antibodies</font>, products       24     ______________________________________________________________________       useful for making humanized or modified <font color="blue">antibodies</font> and processes for making     and using recombinant <font color="blue">antibodies</font></td>
    </tr>
    <tr>
      <td>With respect to VELCADE, on June 26, 2002, Ariad Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>sent     to us and <font color="blue">approximately</font> 50 other parties a <font color="blue">letter offering</font> a sublicense for     the use of <font color="blue"><font color="blue">United States</font> </font>Patent Nodtta 6cmam410cmam516, which is <font color="blue">exclusively licensed</font>     to  Ariad</td>
    </tr>
    <tr>
      <td>If this patent is valid and Ariad <font color="blue">successfully</font> sues us for     infringement, we would require a <font color="blue">license from</font> Ariad in order to <font color="blue">manufacture</font>     and market <font color="blue">VELCADE     </font>  We <font color="blue">may become involved</font> in <font color="blue">expensive patent <font color="blue">litigation</font></font> or other <font color="blue">proceedings</font>,     which  could result in our incurring substantial costs and expenses or     substantial <font color="blue">liability</font> for damages or require us to stop our <font color="blue">development</font> and     <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>There has been substantial <font color="blue">litigation</font> and other <font color="blue">proceedings</font> regarding the     patent and other <font color="blue">intellectual property</font> rights in the <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>We may become a party to patent <font color="blue">litigation</font> or     other <font color="blue">proceedings</font> regarding <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>For example, we     believe that we hold patent <font color="blue">applications</font> that <font color="blue">cover genes</font> that are also     claimed in patent <font color="blue">applications</font> filed by others</td>
    </tr>
    <tr>
      <td><font color="blue">Interference </font><font color="blue">proceedings</font>     before the <font color="blue"><font color="blue">United States</font> </font>Patent and Trademark Office may be <font color="blue">necessary</font> to     <font color="blue">establish which party</font> was the first to invent these genes</td>
    </tr>
    <tr>
      <td>The  cost  to us of any patent <font color="blue">litigation</font> or other proceeding, even if     resolved in our favor, could be substantial</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> may be     able to sustain the cost of such <font color="blue">litigation</font> or <font color="blue">proceedings</font> more <font color="blue">effective</font>ly     than we can because of their <font color="blue">substantially</font> greater financial resources</td>
    </tr>
    <tr>
      <td>If a     patent <font color="blue">litigation</font> or other proceeding is resolved <font color="blue">against us</font>, we or our     <font color="blue"><font color="blue">collaborator</font>s</font> may be <font color="blue">enjoined from</font> developing, <font color="blue">manufacturing</font>, selling or     importing our products or <font color="blue">processes without</font> a <font color="blue">license from</font> the other party     and we may be held liable for <font color="blue">significant</font> damages</td>
    </tr>
    <tr>
      <td>We may not be able to     obtain any required license on <font color="blue">commercially</font> acceptable terms or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting from the <font color="blue">initiation</font> and <font color="blue">continuation</font> of patent     <font color="blue">litigation</font> or other <font color="blue">proceedings</font> could have a material adverse effect on our     ability  to  compete  in  the marketplace</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> and other     <font color="blue">proceedings</font> may also absorb <font color="blue">significant</font> <font color="blue">management</font> time</td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent protection</font> for any compounds that we seek to develop may be     limited to a <font color="blue">particular method</font> of use or <font color="blue">indication</font> such that, if a third     party were to obtain approval of the compound for use in another <font color="blue">indication</font>,     we could be subject to <font color="blue">competition</font> arising from off-label use</td>
    </tr>
    <tr>
      <td>Although we <font color="blue">generally seek</font> the broadest <font color="blue">patent protection</font> available for our     <font color="blue">proprietary</font> compounds, we may not be able to obtain <font color="blue">patent protection</font> for     the <font color="blue">actual composition</font> of any <font color="blue">particular compound</font> and may be limited to     protecting a new method of use for the compound or <font color="blue">otherwise restricted</font> in     our ability to <font color="blue">prevent others from exploiting</font> the compound</td>
    </tr>
    <tr>
      <td>If we are unable     to obtain <font color="blue">patent protection</font> for the <font color="blue">actual composition</font> of any compound that     we seek to develop and <font color="blue">commercialize</font> and <font color="blue">must rely on method</font> of use patent     coverage, we <font color="blue">would likely</font> be unable to prevent others from <font color="blue">manufacturing</font> or     marketing that compound for any use that is not <font color="blue">protected by</font> our patent     rights</td>
    </tr>
    <tr>
      <td>If a <font color="blue">third party</font> were to receive <font color="blue">marketing approval</font> for the compound     for another use, physicians could nevertheless prescribe it for <font color="blue"><font color="blue">indication</font>s</font>     that are not described in the product’s labeling or <font color="blue">approved by</font> the FDA or     other <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Even if we have <font color="blue">patent protection</font> of the     prescribed <font color="blue">indication</font>, as a practical matter, we would have little recourse     as a result of this off-label use</td>
    </tr>
    <tr>
      <td>In that event, our <font color="blue">revenues from</font> the     <font color="blue">commercialization</font> of the compound <font color="blue">would likely</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> our <font color="blue">obligation</font>s in our <font color="blue">intellectual property</font>     licenses with <font color="blue">third parties</font>, we <font color="blue">could lose license rights</font> that are important     to our business</td>
    </tr>
    <tr>
      <td>We are a party to various license <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>In particular, we license     rights to patents for the <font color="blue">formulation</font> <font color="blue">of VELCADE </font>and issued patents relating     to MLN518 and MLN1202</td>
    </tr>
    <tr>
      <td>We may enter into <font color="blue">additional</font> licenses in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">existing licenses impose</font>, and we expect <font color="blue">future licenses will impose</font>,       25     ______________________________________________________________________       various  diligence,  milestone  payment,  royalty, insurance and other     <font color="blue">obligation</font>s on us</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> these <font color="blue">obligation</font>s, the licensor     may have the right to terminate the license, in <font color="blue">which event</font> we might not be     able to market any product that is <font color="blue">covered by</font> the <font color="blue">licensed patents</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Product Manufacturing, Marketing and Sales       Because we have limited sales, marketing and <font color="blue">distribution</font> experience and     <font color="blue">capabilities</font>,  in  some instances we are dependent on <font color="blue">third parties</font> to     <font color="blue">successfully</font> perform these <font color="blue">functions on</font> our behalf, or we may be required to     incur  <font color="blue">significant</font> costs and devote <font color="blue">significant</font> efforts to augment our     existing <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We are marketing and selling VELCADE in the <font color="blue"><font color="blue">United States</font> </font><font color="blue">solely through</font> our     cancer-specific <font color="blue">sales force</font> and without a <font color="blue">collaborator</font></td>
    </tr>
    <tr>
      <td>Our success in     selling VELCADE <font color="blue">will depend <font color="blue">heavily on</font></font> the performance of this <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">areas outside</font> the <font color="blue"><font color="blue">United States</font> </font>where VELCADE has received approval,     <font color="blue">Ortho Biotech </font>or its <font color="blue">affiliates</font> market <font color="blue">VELCADE As </font>a result, our ability to     earn revenue related <font color="blue">to VELCADE </font>outside of the <font color="blue"><font color="blue">United States</font> </font>will depend     <font color="blue">heavily on</font> Ortho Biotech</td>
    </tr>
    <tr>
      <td>SGP <font color="blue">exclusively markets</font> <font color="blue">INTEGRILIN </font>in <font color="blue">areas outside</font> of Europe, including the     United  States, and GSK <font color="blue">exclusively markets</font> <font color="blue">INTEGRILIN </font>in Europe</td>
    </tr>
    <tr>
      <td>As a     result, except for our minimum royalty payments from SGP in 2006 and 2007,     our success in receiving royalties and milestone payments from sales of     <font color="blue">INTEGRILIN </font><font color="blue">depends entirely on</font> the <font color="blue">marketing efforts</font> of these <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td><font color="blue">Depending  </font>on the nature of the products for which we obtain marketing     approval,  we  may  need to rely <font color="blue">significant</font>ly on sales, marketing and     <font color="blue">distribution</font> <font color="blue">arrangement</font>s with our <font color="blue"><font color="blue">collaborator</font>s</font> and other <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>For example, some types of <font color="blue">pharmaceutical</font> products require a large sales     force and extensive marketing <font color="blue">capabilities</font> for <font color="blue">effective</font> <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>If in the future we elect to perform sales, marketing and <font color="blue">distribution</font>     functions for these types of <font color="blue">products ourselves</font>, we would face a number of     <font color="blue">additional</font> risks, including the need to recruit a large number of <font color="blue">additional</font>     experienced marketing and <font color="blue">sales personnel</font></td>
    </tr>
    <tr>
      <td>Because we have no commercial <font color="blue">manufacturing</font> <font color="blue">capabilities</font>, we <font color="blue">will continue</font>     to be dependent on <font color="blue">third party</font> <font color="blue">manufacture</font>rs to <font color="blue">manufacture</font> products for us,     or we will be required to incur <font color="blue">significant</font> costs and devote <font color="blue">significant</font>     efforts to establish our own <font color="blue">manufacturing</font> <font color="blue">facilities</font> and <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>In order to continue     to  develop products, apply for <font color="blue"><font color="blue">regulatory</font> approval</font>s and <font color="blue">commercialize</font>     products, we will need to develop, contract for or otherwise arrange for the     <font color="blue">necessary</font> <font color="blue">manufacturing</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We currently rely <font color="blue">substantially</font> upon <font color="blue">third parties</font> to produce material for     <font color="blue">preclinical testing</font> purposes and expect to continue to do so in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">also currently rely</font> and expect to continue to rely, upon other third     parties, potentially including our <font color="blue"><font color="blue">collaborator</font>s</font>, to produce materials     required  for <font color="blue"><font color="blue">clinical trial</font>s</font> and for the <font color="blue">commercial production</font> of our     products</td>
    </tr>
    <tr>
      <td>There are a limited number of contract <font color="blue">manufacture</font>rs that operate under the     FDA’s good <font color="blue">manufacturing</font> practices <font color="blue">regulations</font> capable of <font color="blue">manufacturing</font> our     products</td>
    </tr>
    <tr>
      <td>If we are unable to arrange for <font color="blue">third party</font> <font color="blue">manufacturing</font> of our     products, or to do so on <font color="blue">commercially</font> <font color="blue">reasonable terms</font>, we may not be able     to complete <font color="blue">development</font> of our products or <font color="blue">commercialize</font> them, or we may     experience delays in doing so</td>
    </tr>
    <tr>
      <td>Reliance on <font color="blue">third party</font> <font color="blue">manufacture</font>rs entails risks to which we would not be     subject if we <font color="blue">manufacture</font>d <font color="blue">products ourselves</font>, including <font color="blue">reliance on</font> the     <font color="blue">third party</font> for <font color="blue">regulatory</font> compliance, the <font color="blue">possibility</font> of breach of the     <font color="blue">manufacturing</font> <font color="blue">agreement</font> by the <font color="blue">third party</font> because of <font color="blue">factors beyond</font> our     control and the <font color="blue">possibility</font> of <font color="blue">termination</font> or non-renewal of the <font color="blue">agreement</font>     by the <font color="blue">third party</font>, <font color="blue">based on</font> its own business priorities, at a time that is     costly or <font color="blue">inconvenient</font> for us</td>
    </tr>
    <tr>
      <td>We may in the <font color="blue">future elect</font> to <font color="blue">manufacture</font> some of our products in our own     <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We would need to invest substantial <font color="blue">additional</font>     funds and <font color="blue">recruit qualified personnel</font> in order to build or lease and operate     any <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       Because we have no commercial <font color="blue">manufacturing</font> capability <font color="blue">for VELCADE </font>and     INTEGRILIN, we are dependent on <font color="blue">third parties</font> to produce <font color="blue">product sufficient</font>     to <font color="blue">meet market demand</font></td>
    </tr>
    <tr>
      <td>We are responsible for managing the supply of material for all clinical and     <font color="blue">commercial production</font> of VELCADE, including VELCADE that <font color="blue">Ortho Biotech </font>sells     or uses in <font color="blue"><font color="blue">clinical trial</font>s</font>, and INTEGRILIN, including <font color="blue">INTEGRILIN </font>that SGP     and GSK sell or use in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">third party</font> contract <font color="blue">manufacture</font>rs to <font color="blue">manufacture</font>, fill/finish     and  package VELCADE for both commercial purposes and for all clinical     trials</td>
    </tr>
    <tr>
      <td>We  have  established  long-term supply relationships for the     production of commercial supplies <font color="blue">of VELCADE </font>We work with one <font color="blue">manufacture</font>r,     with whom we have a long-term supply <font color="blue">agreement</font>, to complete fill/finish for     VELCADE  If  any  of our current <font color="blue">third party</font> <font color="blue">manufacture</font>rs performing     production and fill/finish <font color="blue">for VELCADE </font>are unable or unwilling to continue     performing these services for us and we are unable to find a <font color="blue">replacement</font>     <font color="blue">manufacture</font>r or in the future we are <font color="blue">otherwise unable</font> to <font color="blue">contract with</font>     <font color="blue">manufacture</font>rs to produce commercial supplies <font color="blue">of VELCADE </font>in a cost-<font color="blue">effective</font>     manner, we could run out <font color="blue">of VELCADE </font>for <font color="blue">commercial sale</font> and <font color="blue"><font color="blue">clinical trial</font>s</font>     and our business could be <font color="blue">substantially</font> harmed</td>
    </tr>
    <tr>
      <td>We have no <font color="blue">manufacturing</font> <font color="blue">facilities</font> for <font color="blue">INTEGRILIN </font>and, <font color="blue">accordingly</font>, rely on     third  party  contract  <font color="blue">manufacture</font>rs  for the clinical and commercial     production of <font color="blue">INTEGRILIN </font>We have two <font color="blue">manufacture</font>rs that <font color="blue">currently provide</font>     <font color="blue">us with eptifibatide</font>, the active ingredient <font color="blue">necessary</font> to make <font color="blue">INTEGRILIN </font>    Solvay, one of the current <font color="blue">manufacture</font>rs, owns the process <font color="blue">technology</font> used     by it and the other <font color="blue">manufacture</font>r for the production of <font color="blue">bulk product</font></td>
    </tr>
    <tr>
      <td>As a     result, unless we have an approved <font color="blue">alternative</font> process <font color="blue">technology</font>, we will     be reliant on these <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>We have two <font color="blue">manufacture</font>rs that currently     perform fill/finish services for <font color="blue">INTEGRILIN </font>and a <font color="blue">new packaging supplier</font> for     the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If our current <font color="blue">manufacture</font>rs are unable to continue or     decide to <font color="blue">discontinue</font> their fill/finish services and we are unable to secure     <font color="blue">alternative</font> <font color="blue">manufacture</font>rs, the supply of <font color="blue">INTEGRILIN </font>could be <font color="blue">adversely</font>     <font color="blue">affected which could harm</font> our business</td>
    </tr>
    <tr>
      <td>We have <font color="blue">filed with</font> the FDA for approval of an alternate process <font color="blue">technology</font>     for <font color="blue">INTEGRILIN </font>We <font color="blue">cannot quantify</font> the time or expense that <font color="blue">may ultimately</font>     be required to obtain approval for an alternate process <font color="blue">technology</font>, but it     is possible that such time or <font color="blue">expense could</font> be substantial</td>
    </tr>
    <tr>
      <td>Moreover, we may     not be able to implement any new process <font color="blue">technology</font> <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>In order to mitigate the risk of <font color="blue">INTEGRILIN </font><font color="blue">supply interruption</font>, we have     <font color="blue">entered into</font> a new <font color="blue">third party</font> fill/finish and <font color="blue">bulk product</font> <font color="blue">manufacturing</font>     <font color="blue">arrangement</font> on <font color="blue">commercially</font> <font color="blue">reasonable terms</font> and are currently engaged in     completing a new <font color="blue">third party</font> <font color="blue">arrangement</font> which will <font color="blue">manufacture</font> eptifibatide     utilizing the new process</td>
    </tr>
    <tr>
      <td>We may not be able complete this <font color="blue">third party</font>     <font color="blue">arrangement</font></td>
    </tr>
    <tr>
      <td>Even if we do, if demand for <font color="blue">INTEGRILIN </font>does not meet our     forecasts, the <font color="blue">manufacturing</font> cost under this new <font color="blue">arrangement</font> could be more     <font color="blue">expensive on</font> a per unit <font color="blue">basis than</font> the cost under our existing <font color="blue">arrangement</font>s,     <font color="blue">which would</font> decrease royalty payments due from SGP and would <font color="blue">adversely</font>     affect  our business</td>
    </tr>
    <tr>
      <td>Furthermore, because these are new <font color="blue">manufacturing</font>     <font color="blue">arrangement</font>s, these <font color="blue">manufacture</font>rs may encounter <font color="blue">difficult</font>ies that could     <font color="blue"><font color="blue">adversely</font> affect</font> the supply of <font color="blue">INTEGRILIN </font>and, thereby, harm our business</td>
    </tr>
    <tr>
      <td>If we fail to obtain an <font color="blue">adequate level</font> of <font color="blue">reimbursement</font> for our products by     <font color="blue">third party</font> payors, there may be no <font color="blue">commercially</font> viable markets for our     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> and levels of <font color="blue">reimbursement</font> by <font color="blue"><font color="blue">government</font>al</font> and other third     <font color="blue">party payors affect</font> the market for any <font color="blue">pharmaceutical</font> product or <font color="blue">health care</font>     service</td>
    </tr>
    <tr>
      <td>These <font color="blue">third party</font> payors continually attempt to contain or reduce     the costs of <font color="blue">health care</font> by challenging the <font color="blue">prices charged</font> for medical     products and services</td>
    </tr>
    <tr>
      <td>In some foreign countries, <font color="blue">particularly</font> the countries     of  the European Union, the pricing of <font color="blue">prescription</font> <font color="blue"><font color="blue">pharmaceutical</font>s</font> is     subject to <font color="blue"><font color="blue">government</font>al</font> control</td>
    </tr>
    <tr>
      <td>We may not be able to sell our <font color="blue">products as</font>     <font color="blue">profitably as</font> we expect if we are required to sell our <font color="blue">products at lower</font>     than anticipated prices or <font color="blue">reimbursement</font> is unavailable or limited in scope     or amount</td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________       In particular, <font color="blue">third party</font> payors could lower the amount that they will     <font color="blue">reimburse hospitals</font> or doctors to treat the <font color="blue">conditions</font> for which the FDA has     approved <font color="blue">VELCADE or <font color="blue">INTEGRILIN </font></font>If they do, <font color="blue">pricing levels</font> or <font color="blue">sales volumes</font>     <font color="blue">of VELCADE </font>or <font color="blue">INTEGRILIN </font>may decrease</td>
    </tr>
    <tr>
      <td>In addition, if we fail to comply     with the <font color="blue">rules applicable</font> to the <font color="blue">Medicaid and Medicare </font>programs, we could be     subject to the imposition of civil or <font color="blue">criminal penalties</font> or <font color="blue">exclusion from</font>     these programs</td>
    </tr>
    <tr>
      <td>In foreign markets, a number of <font color="blue">different</font> <font color="blue"><font color="blue">government</font>al</font> and <font color="blue">private entities</font>     determine the <font color="blue">level at which hospitals will</font> be reimbursed for <font color="blue">administering</font>     VELCADE and <font color="blue">INTEGRILIN </font>to insured patients</td>
    </tr>
    <tr>
      <td>If these levels are set, or     reset, too low, it may not be possible to sell <font color="blue">VELCADE or <font color="blue">INTEGRILIN </font></font>at a     profit in these markets</td>
    </tr>
    <tr>
      <td>In both the <font color="blue"><font color="blue">United States</font> </font>and foreign <font color="blue">jurisdictions</font>, there have been a     number of <font color="blue">legislative</font> and <font color="blue">regulatory</font> proposals to change the <font color="blue">health care</font>     system</td>
    </tr>
    <tr>
      <td>For example, the <font color="blue">Medicare Prescription Drug and Modernization Act </font>of     2003  and its <font color="blue">implementing</font> <font color="blue">regulations</font> impose new <font color="blue">requirements</font> for the     <font color="blue">distribution</font>  and  pricing  of <font color="blue">prescription</font> drugs which may affect the     marketing of our products</td>
    </tr>
    <tr>
      <td>These new <font color="blue">requirements</font> have created <font color="blue">uncertainty</font>     <font color="blue">among oncologists</font> and <font color="blue">could impact sales levels</font> <font color="blue">of VELCADE </font><font color="blue">as oncologists</font>     adapt to the new <font color="blue">reimbursement</font> model</td>
    </tr>
    <tr>
      <td>Further proposals are <font color="blue">also likely</font></td>
    </tr>
    <tr>
      <td>The     current <font color="blue">uncertainty</font> and the potential for adoption of <font color="blue">additional</font> proposals     <font color="blue">could affect</font> the timing of <font color="blue">product revenue</font>, our ability to <font color="blue">raise capital</font>,     obtain <font color="blue">additional</font> <font color="blue"><font color="blue">collaborator</font>s</font> and market our products</td>
    </tr>
    <tr>
      <td>In addition, we believe that the <font color="blue">increasing emphasis on managed care</font> in the     <font color="blue"><font color="blue">United States</font> </font>has and <font color="blue">will continue</font> to <font color="blue">put pressure on</font> the price and usage     of our present and future products, which may <font color="blue"><font color="blue">adversely</font> affect</font> product     sales</td>
    </tr>
    <tr>
      <td>Further, when a new <font color="blue">therapeutic</font> product is approved, the <font color="blue">availability</font>     of <font color="blue"><font color="blue">government</font>al</font> or private <font color="blue">reimbursement</font> for that product is uncertain, as     is the amount for which that <font color="blue">product will</font> be reimbursed</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font>     the <font color="blue">availability</font> or amount of <font color="blue">reimbursement</font> for our product <font color="blue">candidates</font>, and     current <font color="blue">reimbursement</font> policies for <font color="blue">VELCADE or <font color="blue">INTEGRILIN </font></font>could change at any     time</td>
    </tr>
    <tr>
      <td>We face a risk of product <font color="blue">liability</font> claims and may not be able to obtain     insurance</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">exposes us</font> to the risk of product <font color="blue">liability</font> claims that is     inherent in the <font color="blue">manufacturing</font>, testing and marketing of human <font color="blue">therapeutic</font>     products</td>
    </tr>
    <tr>
      <td>In particular, VELCADE and <font color="blue">INTEGRILIN </font>are <font color="blue">administered</font> to patients     <font color="blue">with serious diseases</font> who have a <font color="blue">high incidence</font> of mortality</td>
    </tr>
    <tr>
      <td>Although we     have  product <font color="blue">liability</font> insurance that we believe is <font color="blue">appropriate</font>, this     insurance is subject to deductibles, co-insurance <font color="blue">requirements</font> and coverage     <font color="blue">limitations</font> and the market for <font color="blue">such insurance</font> is becoming more <font color="blue">restrictive</font></td>
    </tr>
    <tr>
      <td>We  may  not be able to obtain or maintain <font color="blue">adequate protection against</font>     <font color="blue">potential <font color="blue">liabilities</font></font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">insurance at</font> acceptable     cost or otherwise protect against potential product <font color="blue">liability</font> claims, we     will  be  exposed to <font color="blue">significant</font> <font color="blue">liabilities</font>, which may <font color="blue">materially</font> and     <font color="blue"><font color="blue">adversely</font> affect</font> our business and <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">liabilities</font>     <font color="blue">could prevent</font> or <font color="blue">interfere with</font> our product <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td><font color="blue">Guidelines </font>and <font color="blue">recommendations</font> can affect the use of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Government  </font>agencies  promulgate  <font color="blue">regulations</font>  and <font color="blue"><font color="blue">guidelines</font> directly</font>     applicable to us and to our products</td>
    </tr>
    <tr>
      <td>In addition, professional societies,     practice <font color="blue">management</font> groups, private health and <font color="blue">science foundations</font> and     <font color="blue">organizations</font>  involved in <font color="blue">various diseases from</font> time to time may also     publish  <font color="blue">guidelines</font>  or <font color="blue">recommendations</font> to the <font color="blue">health care</font> and patient     <font color="blue">communities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Recommendations </font>of <font color="blue">government</font> agencies or these other groups or     <font color="blue">organizations</font>  may  relate  to such matters as usage, dosage, route of     <font color="blue">administration</font>  and  use  of <font color="blue">concomitant</font> therapies</td>
    </tr>
    <tr>
      <td><font color="blue">Recommendations </font>or     <font color="blue">guidelines</font>  suggesting  the  reduced use of our products or the use of     <font color="blue">competitive</font> or <font color="blue">alternative</font> products that are <font color="blue">followed by patients</font> and health     <font color="blue">care providers could</font> result in <font color="blue">decreased use</font> of our products</td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________       Risks Relating to an Investment in Our Common Stock       The  trading  price  of our <font color="blue">securities could</font> be subject to <font color="blue">significant</font>     <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> has been quite volatile, and may be     volatile in the future</td>
    </tr>
    <tr>
      <td>During 2005, our <font color="blue">common stock</font> traded as high as     dlra12dtta34  per  share  and  as  low  as  dlra7dtta63 per share</td>
    </tr>
    <tr>
      <td>Factors such as     <font color="blue">announcements</font> of our or our <font color="blue">competitors</font>’ operating results, data from our or     our <font color="blue">competitors</font>’ <font color="blue">clinical trial</font> results, changes in our prospects, market     <font color="blue">conditions</font>   for  bio<font color="blue">pharmaceutical</font>  stocks  in  general  and  analyst     <font color="blue">recommendations</font> or <font color="blue">commentary concerning</font> our or our <font color="blue">competitors</font>’ products or     business could have a <font color="blue">significant</font> <font color="blue">impact on</font> the future <font color="blue">trading price</font>s of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In  particular,  the  trading  price  of  the  common  stock  of  many     bio<font color="blue">pharmaceutical</font> companies, including ours, has experienced <font color="blue">extreme price</font>     and volume <font color="blue">fluctuations</font>, which have <font color="blue">at times been unrelated</font> to the operating     performance  of <font color="blue">such companies whose stocks</font> were affected</td>
    </tr>
    <tr>
      <td>Some of the     factors that may cause <font color="blue">volatility</font> in the price of our securities include:       ·       <font color="blue">product revenue</font>s and the rate of <font color="blue">revenue growth</font>;       ·       <font color="blue">introduction</font> or success of <font color="blue">competitive</font> products;       ·       <font color="blue">clinical trial</font> results and <font color="blue">regulatory</font> <font color="blue">development</font>s;       ·        <font color="blue">quarterly variations</font> in financial results and guidance to the     <font color="blue"><font color="blue">investment community</font> with respect</font> to <font color="blue">future financial</font> results;       ·       business and <font color="blue">product market cycles</font>;       ·       <font color="blue">fluctuations</font> in customer <font color="blue">requirements</font>;       ·       <font color="blue">availability</font> and <font color="blue">utilization</font> of <font color="blue">manufacturing</font> capacity;       ·       timing of new product <font color="blue">introduction</font>s; and       ·       our ability to develop and implement new <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The  price of our <font color="blue">securities may also</font> be <font color="blue">affected by</font> the estimates and     <font color="blue">projections</font> of the <font color="blue">investment community</font> and our ability to meet or exceed     the financial <font color="blue">projections</font> we provide to the public</td>
    </tr>
    <tr>
      <td>The <font color="blue">price may also</font> be     affected  by  general  economic and market <font color="blue">conditions</font>, and the cost of     <font color="blue">operations</font> in our <font color="blue">product markets</font></td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot predict</font> the individual     effect that these factors may have on the price of our securities, these     factors,  either  <font color="blue">individually</font>  or  in  the aggregate, could result in     <font color="blue">significant</font> variations in <font color="blue">price during</font> any <font color="blue">given period</font> of time</td>
    </tr>
    <tr>
      <td>We can not     assure you that these <font color="blue">factors will</font> not have an adverse effect on the trading     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have anti-takeover defenses that <font color="blue">could delay</font> or prevent an <font color="blue">acquisition</font>     and could <font color="blue"><font color="blue">adversely</font> affect</font> the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws <font color="blue">and of Delaware     </font>law  could  have  the  effect  of delaying, deferring or preventing an     <font color="blue">acquisition</font>  of our company</td>
    </tr>
    <tr>
      <td>For example, we have divided our board of     <font color="blue"><font color="blue">directors</font> into three classes</font> that serve staggered three-year terms, we may     issue  shares  of our authorized “blank check” preferred stock and our     <font color="blue">stockholders</font>  are limited in their ability to <font color="blue">call special stockholder</font>     meetings</td>
    </tr>
    <tr>
      <td>In addition, we have <font color="blue">issued preferred stock purchase rights</font> that     would <font color="blue"><font color="blue">adversely</font> affect</font> the economic and <font color="blue">voting interests</font> of a person or     group that seeks to acquire us or a 15prca or <font color="blue">greater interest</font> in our common     <font color="blue">stock without negotiations with</font> our board of <font color="blue">directors</font></td>
    </tr>
  </tbody>
</table>